|1.||Makarov, V K: 6 articles (12/2014 - 06/2009)|
|2.||Mills, Gordon B: 4 articles (02/2011 - 01/2002)|
|3.||Aoki, Junken: 3 articles (02/2015 - 01/2002)|
|4.||Tanaka, Tamotsu: 3 articles (08/2011 - 11/2006)|
|5.||Maache, M: 3 articles (09/2009 - 10/2006)|
|6.||Petavy, A F: 3 articles (09/2009 - 10/2006)|
|7.||Azzouz, S: 3 articles (09/2009 - 10/2006)|
|8.||Osuna, A: 3 articles (09/2009 - 10/2006)|
|9.||Xu, Yan: 3 articles (07/2007 - 03/2002)|
|10.||Liu, Shuying: 3 articles (01/2007 - 08/2004)|
10/01/2009 - "As lysophospholipids are known to accumulate in ischemia heart and to induce arryhthmia, the cPLA2gamma that is abundant in heart may have a protective role through clearance of lysophospholipids by its transacylation activity."
09/01/2004 - "In contrast, phosphatidylserine (PS) and lysophospholipids (LysoPL) were unchanged during ischemia but were elevated after 24 h of reperfusion. "
06/01/1996 - "Incubation of control and ischemic tissue showed no difference in the rate of accumulation of lysophospholipids when the ischemic tissue was obtained from hearts exposed to 15 min of ischemia (107 +/- 4 vs 111 +/- 7 nmol/g dry wt x min, ischemia versus control, mean +/- s.e.m., n = 8), but a significant decrease was noticed in tissue from hearts that had been exposed to 60 min of ischemia (31 +/- 9 vs 86 +/- 18 nmol/g dry wt x min, P < 0.05, n = 4). "
11/01/1995 - "In an in vitro assay system, synaptosomal membranes isolated from MCA cortex 8 and 16 hr after a 60 min ischemia showed a significant decrease in arachidonoyl transfer to lysophospholipids, due mainly to a decrease in lysophospholipid:acylCoA acyltransferase activity. "
08/01/1981 - "Despite significant elevations in lysophospholipids levels, their absolute quantities were very small (0.6% of total phospholipid P) and 15-fold smaller than that reported in vitro to simulate electrophysiological manifestation of ischemia. "
01/01/1990 - "Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results."
03/01/1994 - "Bone marrow purging in acute leukemia with alkyl-lysophospholipids: a new family of anticancer drugs."
11/01/1983 - "Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin."
09/01/1983 - "Alkyl-lysophospholipids lack influence on the occurrence of radiation-induced lymphomas and AKR-leukemia."
06/30/2014 - "We report that CD1c self-reactive T cells recognize a novel class of self-lipids, identified as methyl-lysophosphatidic acids (mLPAs), which are accumulated in leukemia cells. "
|3.||Stomach Ulcer (Gastric Ulcer)
08/01/2011 - "To determine whether lysophosphatidic acids in a foodstuff and Chinese medicine are effective in protecting against gastric ulcer, we subjected rats to water-immersion restraint stress. "
08/01/2011 - "Intragastrically administered lysophosphatidic acids protect against gastric ulcer in rats under water-immersion restraint stress."
|4.||Visceral Leishmaniasis (Kala Azar)
12/01/2011 - "The effects of lysophospholipids (LPLs) on cancer microenvironment is a vast and growing field. "
01/01/2008 - "Lysophosphatidic acids have been found to induce many of the hallmarks of cancer including cellular processes such as proliferation, survival, migration, invasion, and neovascularization. "
01/01/2007 - "If lysophospholipids diffuse from the tumor microenvironment into the bloodstream and persist, they have the potential to serve as early diagnostic markers as well as potential monitors of tumor response to therapy. "
01/01/2007 - "The potential sources of lysophospholipids in the tumor microenvironment include tumor cells and stroma, such as mesothelial cells, as well as inflammatory cells and platelets activated by the proinflammatory tumor environment. "
01/01/2007 - "While many factors contribute to the etiology of cancer, emerging data implicate lysophospholipids acting through specific cell-surface, and potentially intracellular, receptors in acquiring the transformed phenotype propagated during disease. "
|1.||Antineoplastic Agents (Antineoplastics)
|4.||Nonesterified Fatty Acids (NEFA)
|5.||lysophosphatidic acid (MOPA)
|6.||sphingosine 1-phosphate (sphingosine-1-phosphate)
|7.||Phospholipases A2 (Phospholipase A2)
|9.||ruberythric acid (AlP)
|10.||Platelet Activating Factor
|2.||Drug Therapy (Chemotherapy)
|3.||Bone Marrow Purging